Evidence map›Paper›PMID 34252988›Full record

Observational studyMycoses2021

Increased incidence of rhino-orbital mucormycosis in an educational therapeutic hospital during the COVID-19 pandemic in western Iran: An observational study.

Manouchehr Avatef Fazeli, Leila Rezaei, Etrat Javadirad, Khosro Iranfar, Abbas Khosravi, Javad Amini Saman, Pardis Poursabbagh, Mohammad Rasoul Ghadami, Mohammad Mehdi Parandin, Amrollah Dehghani and 9 more

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in Mycoses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. COVID-19 associated mold infections: Review of COVID-19 associated pulmonary aspergillosis and mucormycosis.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2023
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Predictors for mucormycosis in COVID era: A case-control study from Gujarat.Journal of family medicine and primary care · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Manouchehr Avatef FazeliDepartment of Otorhinolaryngology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Leila RezaeiDepartment of Ophthalmology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Etrat JavadiradDepartment of Pathology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Khosro IranfarDepartment of Otorhinolaryngology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Abbas KhosraviDepartment of Ophthalmology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Javad Amini SamanDepartment of Anesthesiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Pardis PoursabbaghDepartment of Otorhinolaryngology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Mohammad Rasoul GhadamiDepartment of Otorhinolaryngology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Mohammad Mehdi ParandinDepartment of Ophthalmology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Amrollah DehghaniDepartment of Otorhinolaryngology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Touraj Ahmadi JouybariDepartment of Interna, Medicine, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Behzad MahdavianDepartment of Infectious Disease, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Nastaran EivaziDepartment of Otorhinolaryngology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Sohbat RezaeiDepartment of Otorhinolaryngology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Alireza RezaeiDepartment of Otorhinolaryngology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Bashir EmamiImam Khomeini and Mohamad Kermanshahi Clinical Research Development Unit, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Mohadeseh HaqgouDepartment of Otorhinolaryngology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Arezoo BozorgomidInfectious Diseases Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.ORCID https://orcid.org/0000-0003-2093-9317
Babak SayadDepartment of Infectious Disease, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Kermanshah University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 patients, especially the patients requiring hospitalisation, have a high risk of several complications such as opportunistic bacterial and fungal infections. Mucormycosis is a rare and opportunistic fungal infection that mainly affects diabetic and immunocompromised patients. An increase has been observed in the number of rhino-orbital mucormycosis in patients with COVID-19 admitted to Imam Khomeini Hospital, Kermanshah, Iran, since October 2020. This is a report of the frequency, risk factors, clinical manifestations, treatment and prognosis of COVID-19 associated with mucormycosis infection.

methodsThe medical records of COVID-19 patients with rhino-orbital mucormycosis who were diagnosed in an educational therapeutic hospital in Kermanshah, west of Iran were surveyed. Several parameters were analysed including demographic, clinical, therapeutic and laboratory characteristics.

resultsTwelve patients with COVID-19-associated rhino-orbital mucormycosis were identified from 12 October to 18 November 2020. All cases reported as proven mucormycosis had a history of hospitalisation due to COVID-19. Comorbidities mainly included diabetes mellitus (83.33%) and hypertension (58.33%). Seventy-five per cent of patients received corticosteroids for COVID- 19 treatment. The sites of involvement were rhino-sino-orbital (83%) and rhino-sino (17%). Amphotericin B/liposomal amphotericin B alone or in combination with surgical debridement or orbital exenteration was used as the first-line therapy. The overall mortality rate was 66.7% (8/12).

conclusionsWe found a high incidence of mucormycosis among COVID-19 patients. Diabetes mellitus and corticosteroid use were the dominant predisposing factor of mucormycosis. Mucormycosis is a life-threatening and opportunistic infection; therefore, physicians should know the signs and symptoms of the disease so that a timely diagnosis and therapy can be performed.

Indexed as

AgedAged, 80 and overCOVID-19FemaleHospitals, TeachingHumansIncidenceIranMaleMiddle AgedMucormycosisOrbital DiseasesRetrospective StudiesRhinitisco-infectionCOVID-19IranmucormycosisSARS-CoV-2

Identifiers

PMID34252988
PMCPMC8447086
OpenAlexW3182583552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.